Coagulation factor VIII

Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.

• Publication year

  1989

• Venue

  Definitions

• Publication date

  1989-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1600-0609.1989.tb00338.x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Sulfur In Proteins

  2016cited by this paper
• New insights into the structural elements involved in the skin haemorrhage induced by snake venom metalloproteinases

  2010cited by this paper
• Long-term high dose factor VIII treatment of 3 haemophiliacs with factor VIII inhibitor.

  2009cited by this paper
• Measurement of antihaemophilic factor A antigen (VII:CAg) with a solid phase immunoradiometric method based on homologous non-haemophilic antibodies.

  2009cited by this paper
• Assay of factor VIII:C with a chromogenic substrate.

  2009cited by this paper
• [Liver transplantation in hemophilia A?].

  1995cited by this paper
• Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.

  1989cited by this paper
• Antigen–Antibody Complex‐Induced Immunosuppression

  1988cited by this paper
• Reconstitution of human factor VIII from isolated subunits.

  1988cited by this paper
• Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy.

  1988cited by this paper
• Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.

  1988cited by this paper
• A simple and accurate microplate assay for the determination of factor VIII activity.

  1987cited by this paper
• INACTIVATION OF FACTOR VIII BY ACTIVATED PROTEIN C AND PROTEIN S

  1987cited by this paper
• [Factor V].

  1987cited by this paper
• Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.

  1987cited by this paper
• A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.

  1987cited by this paper
• Characterization of recombinant human factor VIII.

  1987cited by this paper
• Epitope mapping of functional domains of human factor Va with human and murine monoclonal antibodies. Evidence for the interaction of heavy chain with factor Xa and calcium.

  1987cited by this paper
• von Willebrand factor and von Willebrand disease.

  1987cited by this paper
• Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors).

  1987cited by this paper
• Molecular genetics of hemophilia A in man (factor VIII deficiency).

  1987cited by this paper
• Liver Transplantation in Hemophilia A

  1987cited by this paper
• REMOVAL OF HUMAN ANTIBODIES TO FACTOR VIII :C FROM HEMOPHILIAC PLASMA USING NEW SYNTHETIC SORBENTS

  1987cited by this paper
• On the unreliability of one-stage factor VIII:C clotting assays after infusion of factor VIII concentrates.

  1987cited by this paper
• Glutathione status in constituted physiological fluids containing albumin.

  1987cited by this paper
• Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor.

  1987cited by this paper
• Continuous High-Dose Factor VIII for the Induction of Immune Tolerance in Haemophilia A Patients with High Responder State: A Description of Eleven Patients Treated

  1987cited by this paper
• Monoclonal antibodies to factor VIII: their application in immunoblotting for the visualization of factor VIII in therapeutic concentrates and plasma

  1987cited by this paper
• THE FUNCTIONAL DOMAINS OF COAGULATION FACTOR VIII

  1987cited by this paper
• An effect of predilution on VIII:C determination by the one-stage assay.

  1987cited by this paper
• The effect of thrombin on the complex between factor VIII and von Willebrand factor.

  1987cited by this paper
• Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders.

  1987cited by this paper
• The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins

  1987cited by this paper
• Two independent domains of factor VIII co-expressed using recombinant vaccinia viruses have procoagulant activity.

  1987cited by this paper
• The role of cysteine oxidation in the thermal inactivation of T4 lysozyme.

  1987cited by this paper
• Choosing a Host Cell for Active Recombinant Factor VIII Production Using Vaccinia Virus

  1987cited by this paper
• A potential new procedure for removing anti-factor VIII antibodies from hemophilic plasma.

  1987cited by this paper
• Identification of six functional clotting factor VIII:C epitopes by analysis of cross-reactive public idiotypes in murine monoclonal VIII:C inhibitors.

  1987cited by this paper
• Localization of factor VIII-procoagulant antigen: an immunohistological survey of the human body using monoclonal antibodies.

  1986cited by this paper
• Monoclonal Antibodies and the Haemostasis Laboratory: Current Position

  1986cited by this paper
• Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.

  1986cited by this paper
• A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.

  1986cited by this paper
• Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.

  1986cited by this paper
• Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.

  1986cited by this paper
• Monoclonal Antibodies as Drugs or Devices: Practical and Regulatory Aspects

  1986cited by this paper
• Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule.

  1986cited by this paper
• Enzyme linked immunosorbent assay (ELISA) for the measurement of factor VIII coagulant antigen (CAg) using haemophilic antibodies

  1986cited by this paper
• The regulation of hemostasis: the protein C system.

  1986cited by this paper
• Characterization, mapping, and expression of the human ceruloplasmin gene.

  1986cited by this paper
• A simple method for ranking the affinities of monoclonal antibodies.

  1986cited by this paper
• Room Temperature, Microtray Chromogenic Assay of Factor VIII:C

  1986cited by this paper
• The functional domains of coagulation factor VIII:C.

  1986cited by this paper
• Preparation of high purity factor VIII concentrates.

  1986cited by this paper
• Analysis of whole blood manganese by flameless atomic absorption spectrophotometry and its use as an indicator of manganese status in animals.

  1986cited by this paper
• A simple method for ranking the affinities of monoclonal antibodies.

  1986cited by this paper
• The Production and Characterisation of a Panel of Ten Murine Monoclonal Antibodies to Human Procoagulant Factor VIII

  1986cited by this paper
• Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.

  1985cited by this paper
• Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies.

  1985cited by this paper
• Prenatal diagnosis of classic hemophilia (hemophilia A) by immunoradiometric assays.

  1985cited by this paper
• Distribution of factor VIII mRNA and antigen in human liver and other tissues

  1985cited by this paper
• Detection and sequence of mutations in the factor VIII gene of haemophiliacs         

  1985cited by this paper
• Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene

  1985cited by this paper
• Factor VIII gene specific probe for prenatal diagnosis of haemophilia A.

  1985cited by this paper
• Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

  1985cited by this paper
• Clinical Application of a Chromogenic Substrate Method for Determination of Factor VIII Activity

  1985cited by this paper
• Standard Nomenclature for Factor VIII and von Willebrand Factor: A Recommendation by the International Committee on Thrombosis and Haemostasis

  1985cited by this paper
• Modulation of thrombin-mediated activation of factor VIII:C by calcium ions, phospholipid, and platelets.

  1985cited by this paper
• Characterization of the Polypeptide Composition of Human Factor VIII:C and the Nucleotide Sequence and Expression of the Human Kidney cDNA

  1985cited by this paper
• Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate.

  1985cited by this paper
• Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

  1985cited by this paper
• FACTOR VIII:C SYNTHESIS IN THE KIDNEY

  1985cited by this paper
• Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation.

  1985cited by this paper
• Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes.

  1985cited by this paper
• Registry of Monoclonal Antibodies to Factor VIII and von Willebrand Factor

  1985cited by this paper
• The natural history of factor VIII inhibitors in patients with hemophilia A.

  1984cited by this paper
• New alternatives and strategies in the treatment of inhibitors.

  1984cited by this paper
• Extracorporeal protein A-sepharose and specific affinity chromatography for removal of antibodies.

  1984cited by this paper
• There is no correlation between vitamin K dependent coagulant content and clinical effectiveness of activated and standard factor IX complex concentrates.

  1984cited by this paper
• Factor VIII inhibitor treatment with high doses of F VIII.

  1984cited by this paper
• Purification of the factor VIII complex.

  1984cited by this paper
• Localization of factor VIIIC: antigen in guinea‐pig tissues and isolated liver cell fractions

  1984cited by this paper
• Molecular cloning of a cDNA encoding human antihaemophilic factor

  1984cited by this paper
• Overview of inhibitors to factor VIII and IX.

  1984cited by this paper
• Induced immunotolerance in factor VIII inhibitor patients.

  1984cited by this paper
• Coagulation Factor V contains copper ion.

  1984cited by this paper
• Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate

  1984cited by this paper
• HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA.

  1984cited by this paper
• New alternatives and strategies in the treatment of inhibitors.

  1984cited by this paper
• Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid.

  1984cited by this paper
• Efficacy of porcine factor VIII in the management of haemophiliacs with inhibitors

  1984cited by this paper
• Structure of human factor VIII

  1984cited by this paper
• Use of Porcine Factor VIII in the Management of Seventeen Patients with Factor VIII Antibodies

  1984cited by this paper
• Expression of active human factor VIII from recombinant DNA clones

  1984cited by this paper
• Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII.

  1984cited by this paper
• Isolation of molecules recognized by monoclonal antibodies and antisera: the solid phase immunoisolation technique.

  1984cited by this paper
• Active mechanisms of immunological tolerance

  1984cited by this paper
• Induced immunotolerance in factor VIII inhibitor patients.

  1984cited by this paper
• There is no correlation between vitamin K dependent coagulant content and clinical effectiveness of activated and standard factor IX complex concentrates.

  1984cited by this paper
• Single-chain structure of human ceruloplasmin: the complete amino acid sequence of the whole molecule.

  1984cited by this paper
• The natural history of factor VIII inhibitors in patients with hemophilia A.

  1984cited by this paper

• The History of Rare Bleeding Disorders

  2024cites this paper
• Application of non-metal nanoparticles, as a novel approach, for improving the stability of blood products: 2011–2021

  2022cites this paper
• Platelets count and Fibrinogen level with Type I and Type II Diabetes Mellitus Patients in Khartoum State

  2008cites this paper